On February 14, 2023 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, reported its financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023 (Press release, Mirati, FEB 14, 2023, View Source [SID1234627215]). During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 2312901. A replay of the call will be available approximately 2 hours after the event has ended at the same website.